Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04910568 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04910568 · ClinicalTrials.gov record · last posted 2026-08-20

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

Study acronym: CAMMA 1
StatusRecruiting
PhasePhase 1
Started2021-07-26
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.

Protocol amendment history 5 changes detected by DataLookout

2026-08-21
Enrollment reopened
2026-08-21
Trial sites expanded: 25 → 34 locations
2026-08-18
Enrollment increased: 126 → 186 participants
2026-07-07
Primary completion moved earlier: 2029-12-10 → 2028-12-21
2026-07-07
Completion moved earlier: 2029-12-10 → 2028-12-21
Trial Details
NCT Number NCT04910568
Lead Sponsor Genentech, Inc.
Collaborators: Hoffmann-La Roche
Conditions Multiple Myeloma
Enrollment 186 participants
Start Date 2021-07-26
Primary Completion 2028-12-21 (estimated)
Study Completion 2028-12-21 (estimated)
Updated on ClinicalTrials.gov 2026-08-20